CSPC Innovation Pharmaceutical Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de CSPC Innovation Pharmaceutical de 37.5% y 36% por año respectivamente. Se prevé que el BPA crezca en un 34.3% al año. Se espera que la rentabilidad financiera sea de 13.7% en 3 años.

Información clave

37.5%

Tasa de crecimiento de los beneficios

34.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	18.8%
Tasa de crecimiento de los ingresos	36.0%
Rentabilidad financiera futura	13.7%
Cobertura de analistas	Good
Última actualización	06 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Are CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) Investors Paying Above The Intrinsic Value?

Nov 21

Why CSPC Innovation Pharmaceutical's (SZSE:300765) Shaky Earnings Are Just The Beginning Of Its Problems

Oct 31

Earnings Tell The Story For CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) As Its Stock Soars 27%

Sep 30

Estimating The Fair Value Of CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765)

Aug 16

CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) 27% Share Price Plunge Could Signal Some Risk

Jul 04

CSPC Innovation Pharmaceutical's (SZSE:300765) Weak Earnings May Only Reveal A Part Of The Whole Picture

Apr 29

CSPC Innovation Pharmaceutical (SZSE:300765) Will Pay A Larger Dividend Than Last Year At CN¥0.32

Apr 25

CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) P/E Still Appears To Be Reasonable

Apr 24

Previsiones de crecimiento de beneficios e ingresos

SZSE:300765 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	5,115	1,116	1,539	1,085	6
12/31/2025	3,987	819	852	1,042	6
12/31/2024	2,436	400	128	272	6
9/30/2024	2,043	513	-85	-21	N/A
6/30/2024	2,129	628	-702	-544	N/A
3/31/2024	2,307	705	-404	-344	N/A
12/31/2023	2,502	756	832	927	N/A
9/30/2023	2,671	591	-313	174	N/A
6/30/2023	2,729	659	681	910	N/A
3/31/2023	2,804	732	667	831	N/A
1/1/2023	2,626	726	527	641	N/A
9/30/2022	2,694	666	294	582	N/A
6/30/2022	2,384	562	225	461	N/A
3/31/2022	2,034	433	113	350	N/A
1/1/2022	1,850	393	97	292	N/A
9/30/2021	1,333	287	167	250	N/A
6/30/2021	1,338	284	188	277	N/A
3/31/2021	1,319	311	201	302	N/A
12/31/2020	1,317	300	231	349	N/A
9/30/2020	1,329	317	246	396	N/A
6/30/2020	1,290	316	199	344	N/A
3/31/2020	1,270	290	228	357	N/A
12/31/2019	1,257	273	209	315	N/A
9/30/2019	1,299	266	163	223	N/A
6/30/2019	1,277	251	159	233	N/A
3/31/2019	1,281	230	140	191	N/A
12/31/2018	1,240	224	101	160	N/A
9/30/2018	1,149	214	68	119	N/A
6/30/2018	1,111	198	N/A	49	N/A
3/31/2018	1,064	191	N/A	18	N/A
12/31/2017	1,031	195	N/A	1	N/A
12/31/2016	890	207	N/A	137	N/A
12/31/2015	742	116	N/A	112	N/A
12/31/2014	651	108	N/A	93	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (37.5% al año) de 300765 es superior a la tasa de ahorro (2.8%).

Beneficios vs. Mercado: Se prevé que los beneficios (37.5% al año) de 300765 crezcan más rápidamente que el mercado CN (26.2% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de 300765 crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (36% al año) de 300765 crezcan más rápidamente que los del mercado CN (13.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (36% al año) de 300765 crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 300765 sea baja dentro de 3 años (13.7%).

CSPC Innovation Pharmaceutical Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates fall by 10%

Price target increased by 7.6% to CN¥41.19

Price target increased by 7.0% to CN¥43.00

Consensus EPS estimates fall by 10%

Price target increased by 70% to CN¥49.46

Recent updates

Are CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) Investors Paying Above The Intrinsic Value?

Now 24% overvalued after recent price rise

Investor sentiment deteriorates as stock falls 18%

Why CSPC Innovation Pharmaceutical's (SZSE:300765) Shaky Earnings Are Just The Beginning Of Its Problems

Consensus EPS estimates fall by 10%

Third quarter 2024 earnings released: EPS: CN¥0.002 (vs CN¥0.13 in 3Q 2023)

Investor sentiment deteriorates as stock falls 16%

Price target increased by 7.6% to CN¥41.19

Earnings Tell The Story For CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) As Its Stock Soars 27%

CSPC Innovation Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 24%

Now 21% overvalued after recent price rise

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: CN¥0.043 (vs CN¥0.16 in 2Q 2023)

Estimating The Fair Value Of CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765)

Now 24% overvalued

Now 20% overvalued

CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) 27% Share Price Plunge Could Signal Some Risk

Price target increased by 7.0% to CN¥43.00

CSPC Innovation Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 17, 2024

Consensus EPS estimates fall by 10%

CSPC Innovation Pharmaceutical's (SZSE:300765) Weak Earnings May Only Reveal A Part Of The Whole Picture

CSPC Innovation Pharmaceutical (SZSE:300765) Will Pay A Larger Dividend Than Last Year At CN¥0.32

Dividend of CN¥0.32 announced

First quarter 2024 earnings released: EPS: CN¥0.068 (vs CN¥0.16 in 1Q 2023)

CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) P/E Still Appears To Be Reasonable

CSPC Innovation Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024

CSPC Innovation Pharmaceutical Co., Ltd., Annual General Meeting, Apr 09, 2024

CSPC Innovation Pharmaceutical Co., Ltd., Annual General Meeting, Apr 09, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 23%

Price target increased by 70% to CN¥49.46

High number of new and inexperienced directors

CSPC Innovation Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 15, 2024

Investor sentiment improves as stock rises 19%

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 34%

Third quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.16 in 3Q 2022)

Investor sentiment improves as stock rises 20%

CSPC Innovation Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 25, 2023

CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) announces an Equity Buyback for CNY 421.8 million worth of its shares.

CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765) announces an Equity Buyback for CNY 421.8 million worth of its shares.

Investor sentiment improves as stock rises 17%

Second quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.20 in 2Q 2022)

CSPC Innovation Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

Now 21% undervalued

High number of new and inexperienced directors

Investor sentiment improves as stock rises 15%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.29 (vs CN¥0.15 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.14 in 2Q 2021)

CSPC Innovation Pharmaceutical Co., Ltd. announced that it expects to receive CNY 500 million in funding

Investor sentiment improved over the past week

CSPC Innovation Pharmaceutical Co., Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on June 7, 2022

First quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.15 in 1Q 2021)

CSPC Innovation Pharmaceutical Co., Ltd. Approves Cash Dividend (Tax Included) for the Year 2021

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.14 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.20 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.13 in 1Q 2020)

CSPC Innovation Pharmaceutical Co., Ltd., Annual General Meeting, Mar 26, 2021

Full year 2020 earnings released: EPS CN¥0.71 (vs CN¥0.69 in FY 2019)

New 90-day low: CN¥16.49

CSPC Innovation Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 05, 2021

New 90-day low: CN¥17.89